CTi Biopharma Corp

CTi Biopharma — Investor Presentation (January 2015)

33 slides from CTi Biopharma's investor presentation, Jan 13, 2015

  1. Slide 1: Corporate Presentation

    Exhibit 99.1 Conquering Cancer. It’s in our blood.™ CORPORATE PRESENTATION San Francisco – January 13, 2015 © Copyright 2015 CTI BioPharma Corp. All rights reserved.

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or a

  3. Slide 3: Accomplishments in 2014

    Accomplishments in 2014 Building Shareholder Value Entered into a $133 million* collaboration for PIXUVRI to expand commercial potential of product Advanced pacritinib Phase 3 program in myelofibrosis; completed 1 st Phase 3 trial and received $20mm from Baxter Reported preclinical data highlighting

  4. Slide 4: 2015 Key Objectives

    2015 Key Objectives Pacritinib • Report top-line results from PERSIST-1 Phase 3 MF trial late 1Q-2015 • Complete enrollment of PERSIST-2 mid-2015 • Begin rolling submission of NDA late 2015 • Advance development program in other hematologic malignancies PIXUVRI • Generate sufficient E.U. sales to ac

  5. Slide 5: Preliminary 2015 Revenue Projections

    Preliminary 2015 Revenue Projections $80 Preliminary Year-Over-Year Revenue Comparison* $70 $60 Projected range of $50 $55mm - $72mm $40 $30 $20 $10 $- 2013 Actual 2014 E* 2015E * *This estimate is unaudited, preliminary and may change. CTI BioPharma and its auditors have not completed our normal an

  6. Slide 6: Strategic Approach to Commercialize Globally

    Strategic Approach to Commercialize Globally U.S. Europe ROW Develop Full Core Markets Collaboration [North Western Europe] Commercial For PIXUVRI, pacritinib Capabilities Commercializing PIX and tosedostat and future products For pacritinib*; PIXUVRI • SERVIER for PIXUVRI and tosedostat • Cost-effe

  7. Slide 7: Building a Successful Oncology Business

    Building a Successful Oncology Business Therapeutic Focus: Novel Targeted Therapies Blood-Related Cancers MPNs Leukemia Lymphoma MF and PV AML and MDS NHL and CLL 7

  8. Slide 8: CTI BioPharma Opportunity

    CTI BioPharma Opportunity nd 1st approved therapy in the E.U. for relapsed aggressive B-cell NHL beyond 2 line; ongoing confirmatory Phase 3 trial Targeting cash flow positive operations in 2015 Collaboration with SERVIER of up to ~$133* million Fast Track designated product candidate Phase 3 top-li

  9. Slide 9: Pacritinib

    Pacritinib

  10. Slide 10: Myelofibrosis: A Chronic Disease

    Myelofibrosis: A Chronic Disease • Malignant bone marrow disorder triggers an inflammatory response, scarring the bone marrow and limiting its ability to produce blood cells prompting the spleen and liver to compensate • Symptoms include: enlargement of the spleen, anemia, thrombocytopenia, extreme

  11. Slide 11: Pacritinib: Market Opportunity in MF

    Pacritinib: Market Opportunity in MF • Approved drug Jakafi ®/Jakavi® (ruxolitinib) Total 2014 U.S. net sales estimated at $350-360mm 1; $600mm - $1bn 2015 run-rate worldwide • Treatment emergent thrombocytopenia and anemia are limitations of most JAK1/JAK2 inhibitors, including ruxolitinib • Market

  12. Slide 12: Evaluating Pacritinib in All MF Patients

    Evaluating Pacritinib in All MF Patients Fast Track Designation; Global Registration Program • PERSIST-1 compares pacritinib to BAT, excludes ruxolitinib All MF • Fully enrolled; Top-line results expected late in 1Q-2015 Patients • Most inclusive randomized Phase 3 study • INT-1, 2 High risk, no res

  13. Slide 13: PERSIST-1 Representative of MF Population

    PERSIST-1 Representative of MF Population Distribution (%) Platelets Projected Distribution (%) 1-3 in MF Patients Platelets in MF Patient in PERSIST-1 4 16 10 19 11 63 15 54 12 >150,000/µL 100- 150,000/µL >150,000/µL 100-150,000/µL 50-100,000/µL <50,000/µL 50-100,000/µL <50,000/µL The duration of t

  14. Slide 14: PERSIST Program Phase 3 Trial - Timeline

    PERSIST Program Phase 3 Trial - Timeline July 2014: PERSIST-1 enrollment complete; March 2014: $20mm Open milestone enrollment for PERSIST-2 March 2015: Expect to report PERSIST-1 top-line November 2013: results June 2012: BAXTER Acquired collaboration pacritinib from October 2013: 460mm upfront S*B

  15. Slide 15: Pacritinib: Unique Kinome Profile

    Pacritinib: Unique Kinome Profile1 • Pacritinib is an oral multikinase inhibitor with specificity for kinases in several unrelated families • The inhibition of IRAK1 and c-fms (CSF1R) may contribute to its anti-inflammatory activity and early onset of symptomatic benefit in MF • Suggests its potenti

  16. Slide 16: Pacritinib: AML Target Indication

    Pacritinib: AML Target Indication • Able to target multiple pathways, including suppression of microenvironmental tumor interactions that are key to overcoming Signaling pathways initiated by FLT3 longer-term drug resistance in this disease ligand activation of the FLT3 receptor • FLT3 strong progno

  17. Slide 17: Pacritinib: Key Takeaways

    Pacritinib: Key Takeaways • Oral JAK2/FLT3 inhibitor that lacks treatment emergent myelosuppression associated with marketed JAK1/JAK2 agent - Potential to demonstrate superior disease and symptom control over titrated doses of ruxolitinib - May be used in combination regimens w/o overlapping myelos

  18. Slide 18: Pacritinib: Collaboration with Baxter

    Pacritinib: Collaboration with Baxter Announced November 2013 • CTI and BAXTER: Joint commercialization, profit split in U.S. • BAXTER: Exclusive rights to commercialize in all indications outside U.S., BAXTER generally responsible for 75% of global development Summary of Financial Terms • Potential

  19. Slide 19: PIXUVRI

    PIXUVRI®

  20. Slide 20: PIXUVRI: Fulfilling An Unmet Clinical Need

    PIXUVRI: Fulfilling An Unmet Clinical Need st nd rd 1 LINE 2 LINE 3 LINE+ • Typically • Intensive (toxic) • Palliative care anthracycline- non-anthracycline (symptom control) based treatment based salvage or clinical trials R-CHOP therapy (R-DHAP), +/- ASCT • Curative in 50% - 1 55% of patients • Al

  21. Slide 21: PIXUVRI: Overview

    PIXUVRI: Overview One of the most active agents in R/R aggressive B-cell NHL where there was no standard therapy • Novel MOA: DNA alkylation/mitotic instability PIXUVRI appears to be impairing chromosomal segregation during mitosis, thereby generating loss of genetic material in daughter cells, an a

  22. Slide 22: PIXUVRI: Demonstrated Benefit in Phase 3

    PIXUVRI: Demonstrated Benefit in Phase 3 PIX301* - Only randomized controlled Phase 3 trial in 3 rd-line aggressive B-cell NHL (n=140 patients) Patient Population • Heavily pre-treated patients; median of 3 prior treatments • Median age was 60 years rd ITT Population 3 /4 th Line B-cell Results PIXU

  23. Slide 23: PIXUVRI: Approved as Monotherapy by EMA

    PIXUVRI: Approved as Monotherapy by EMA st • 1 and only approved monotherapy in the rd th E.U. for aggressive B-cell NHL 3 /4 line nd rd nd • 2 salvage (3 line) = 2 chance at potentially curative ASCT* • Durable rd th remissions and disease control (3 /4 line) in non-SCT eligible • Label expansion s

  24. Slide 24: PIXUVRI: PIX306 Study

    PIXUVRI: PIX306 Study Post-marketing Commitment Phase 3 Study Eligibility Criteria Pixantrone* Primary Endpoint 1:1 Rituximab PFS Relapse after CHOP-R therapy or an equivalent Randomization regimen and are Secondary n = ~220 Gemcitabine* Endpoints ineligible for stem cell transplant Rituximab CR ORR

  25. Slide 25: PIXUVRI EU Sales Since Launch

    PIXUVRI EU Sales Since Launch Net PIXUVRI Sales by Quarter ($ in millions) 2.5 2 1.5 1 0.5 0 Q2 Q3 Q4 Q1 Q2 Q3 2013 2014 Focus on Reimbursement Germany UK Netherlands 25

  26. Slide 26: PIXUVRI: Maximizing the European Commercial Opportunity

    PIXUVRI: Maximizing the European Commercial Opportunity • Exclusive license and collaboration agreement with SERVIER to develop and expand commercial reach 10+ Countries • Reimbursed in Austria, England/Wales, Germany, ~5,000 Netherlands Current eligible patients • Standard of care per treatment gui

  27. Slide 27: PIXUVRI Collaboration with SERVIER

    PIXUVRI Collaboration with SERVIER Announced September 2014 • Exclusive license and collaboration agreement to develop and expand commercial reach of PIXUVRI • CTI retains 100% U.S. rights, continues its commercial presence in UK, Germany/Austria, Nordics, and via distribution partners in Turkey, Is

  28. Slide 28: Continued Growth Expected in aNHL in 2015

    Continued Growth Expected in aNHL in 2015 • Continue to build awareness and educate HCPs • Expand field force; medical science liaisons key • Growing body of evidence on potential for combination studies • Limited near-term competition expected 28

  29. Slide 29: Tosedostat

    Tosedostat

  30. Slide 30: Tosedostat

    Tosedostat Novel Treatment for Blood-Related Cancers: MDS & AML • Oral, once-daily, aminopeptidase inhibitor interferes with protein recycling, prevents breakdown of peptides into amino acids necessary for tumor cell survival • Synergy with targeted agents (HMA, proteosome inhibitors) or chemotherap

  31. Slide 31: Financial Overview

    Financial Overview Capital Structure and Financial Statistics Exchanges NASDAQ and MTA: CTIC Market Capitalization* ~$417mm Shares Outstanding** ~177mm Cash as of November 30, 2014 $82mm Debt $20mm *As of January 9, 2015 stock price of $2.36 per share. ** As of December 15, 2014. 31

  32. Slide 32: Why Invest in CTI BioPharma?

    Why Invest in CTI BioPharma? Biopharmaceutical company with a marketed oncology drug in the E.U. Strategic partner provides validation, financial resources and commercial support for high-potential JAK2/FLT3 inhibitor Phase 3 program Building value through development of late-stage pipeline, with em

  33. Slide 33: Thank You!

    THANK YOU! Ctl BIOPHARMA NASDAQ & MTA: CTIC

CTI Biopharma — Investor Presentation (January 2015) on 6ix